Pharmaceutical Technology on MSN2d
Arbor to advance gene editing treatments with $73.9m fundingThe funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.
As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...
The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.
including EW Healthcare Partners, MVM and Revelation Partners. Trinity Capital provided the debt financing. VitalConnect CEO Peter Van Haur commented: “Our best-in-class proprietary biosensor ...
The equity fundraising was led by first-time investor Ally Bridge Group, plus additions from previous backers at EW Healthcare Partners, MVM and Revelation Partners. Trinity Capital provided the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback